Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex

Fig. 2

Impact of metabolic dysfunction-associated fatty liver disease (MAFLD), metabolic syndrome (MetS), and type 2 diabetes (DM) on cardiovascular disease. A Impact of MAFLD, MetS, and DM on coronary artery disease (CAD). B Impact of MAFLD, MetS, and DM on cerebrovascular disease (CVD). Analysis was performed using a Cox proportional hazards model adjusted for age, sex, current smoking, LDL-C and use of statin. *P < 0.001 vs. Group with neither MAFLD, MetS nor DM. **P < 0.01 vs. Group with neither MAFLD, MetS nor DM. MAFLD, metabolic dysfunction-associated fatty liver disease; MetS, metabolic syndrome; DM, type 2 diabetes; HR, hazard ratio

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840